From an alternative perspective, studies pointed out that chemotherapy-resistant MM patient samples and cells appear to express lower levels of BiP, GRP94, Beclin-1, and LC3-II compared to sensitive samples. This evidence concerns the gene HSPA5 and Miyoshi myopathy.